<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty patients with several histologic subtypes of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who had become resistant to combination chemotherapy were treated with a five-day course of the epipodophyllotixin <z:chebi fb="0" ids="4911">VP-16</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Of 19 evaluable patients, 8 (42%) responded to treatment with 1 complete response and 7 partial responses </plain></SENT>
<SENT sid="2" pm="."><plain>The median duration of response was 5.5 months </plain></SENT>
<SENT sid="3" pm="."><plain>Seven of the responders had a diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 1 had a nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the responders who had diffuse histiocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DHL), diffuse mixed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DML), and diffuse undifferentiated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DUL)--the more aggressive histologies in the Rappaport classification--6 of 13 (46%) evaluable patients responded to therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Responses were seen in node-dominant, skin-dominant, and marrow-dominant disease </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity was mainly hematopoietic, 53% of patients experiencing <z:hpo ids='HP_0001882'>leukopenia</z:hpo> ( less than 2,000 cells per cu mm) and 68% of patients experiencing thrombocytopenian 2,000 cells per cu mm) and 68% of patients experiencing <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> ( less than 100,000 platelets per cu mm) </plain></SENT>
<SENT sid="7" pm="."><plain>There were two <z:hpo ids='HP_0011420'>deaths</z:hpo> attributable to profound <z:hpo ids='HP_0001882'>leukopenia</z:hpo> with <z:hpo ids='HP_0100806'>sepsis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The activity of <z:chebi fb="0" ids="4911">VP-16</z:chebi> in patients who have previously been extensively treated with multiple drugs including <z:chebi fb="0" ids="28445">vincristine</z:chebi> supports its activity in the <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and suggests its lack of cross-resistance with <z:chebi fb="0" ids="28445">vincristine</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>The inclusion of <z:chebi fb="0" ids="4911">VP-16</z:chebi> in primary treatment protocols in the diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> should be considered </plain></SENT>
</text></document>